Liver cancer results in enormous human toll worldwide. Over the years, various chemotherapeutic entities have been employed for treatment of advanced HCC; however, as of yet none embody attributes to improve overall survival. Following rapid advancement in nanotechnology, it is envisage that nanoscale systems may emerge as intriguing platforms to improve chemotherapeutic strategies against various cancers including liver cancer; with better insight in the understanding of pathophysiology of liver cancer and material science, the field of nanotechnology may bring newer hope to liver cancer treatment. Reckoning with these, we detailed the arsenal of nanoformulations that are in various stages of clinical development/ preclinical settings for the treatment of liver cancer together with providing a glimpse of the attributes of nanotechnology in revolutionizing the status of chemotherapeutic modalities.

Keywords:
Nanoparticle, Hepatocellular carcinoma, Nanodoxorubicin, Thermodox, SMANCS
1.
Wong R, Frenette C: Updates in the management of hepatocellular carcinoma. Gastroenterol Hepatol (N Y) 2011;7:16-24.
2.
Kanwal F, Befeler A, Chari RS, et al: Potentially curative treatment in patients with hepatocellular cancer - results from the liver cancer research network. Aliment Pharmacol Ther 2012;36:257-265.
3.
Huang M, Liu G: The study of innate drug resistance of human hepatocellular carcinoma Bel7402 cell line. Cancer Lett 1999;135:97-105.
4.
Shapira A, Livney YD, Broxterman HJ, Assaraf YG: Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance. Drug Resist Updat 2011;14:150-163.
5.
Duncan R: Polymer therapeutics as nanomedicines: new perspectives. Curr Opin Biotechnol 2011;22:492-501.
6.
Farokhzad OC, Langer R: Impact of nanotechnology on drug delivery. ACS Nano 2009;3:16-20.
7.
Xie J, Lee S, Chen X: Nanoparticle-based theranostic agents. Adv Drug Deliv Rev 2010;62:1064-1079.
8.
Li FR, Yan WH, Guo YH, Qi H, Zhou HX: Preparation of carboplatin-Fe@C-loaded chitosan nanoparticles and study on hyperthermia combined with pharmacotherapy for liver cancer. Int J Hyperthermia 2009;25:383-391.
9.
Ray K: Liver cancer: the promise of new approaches in the management of hepatocellular carcinoma - adding to the toolbox? Nat Rev Gastroenterol Hepatol 2013;10:195.
10.
Schmidinger M, Wenzel C, Locker GJ, et al: Pilot study with pegylated liposomal doxorubicin for advanced or unresectable hepatocellular carcinoma. Br J Cancer 2001;85:1850-1852.
11.
Falkson G, Moertel CG, Lavin P, Pretorius FJ, Carbone PP: Chemotherapy studies in primary liver cancer: a prospective randomized clinical trial. Cancer 1978;42:2149-2156.
12.
Falkson G, MacIntyre J, Shutt AJ, et al: Neocarzinostatin versus mAMSA or doxorubicin in hepatocellular carcinoma. J Clin Oncol 1984;2:581-584.
13.
Lai CL, Wu PC, Chan GC, Lok AS, Lin HJ: Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer 1988;62:479-483.
14.
Vasey PA, Kaye SB, Morrison R, et al: Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin Cancer Res 1999;5:83-94.
15.
Schroeder A, Heller DA, Winslow MM, Dahlman JE, Pratt GW, Langer R, Jacks T, Anderson DG: Treating metastatic cancer with nanotechnology. Nat Rev Cancer 2011;12:39-50.
16.
Kong G, Anyarambhatla G, Petros WP, et al: Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release. Cancer Res 2000;60:6950-6957.
17.
Poon RT, Borys N: Lyso-thermosensitive liposomal doxorubicin: an adjuvant to increase the cure rate of radiofrequency ablation in liver cancer. Future Oncol 2011;7:937-945.
18.
Lorusso D, Di Stefano A, Carone V, Fagotti A, Pisconti S, Scambia G: Pegylated liposomal doxorubicin-related palmar - plantar erythrodysesthesia (‘hand-foot' syndrome. Ann Oncol 2007;18:1159-1164.
19.
Patel NR, Pattni BS, Abouzeid AH, Torchilin VP: Nanopreparations to overcome multidrug resistance in cancer. Adv Drug Deliv Rev 2013;65:1748-1762.
20.
Reddy LH, Couvreur P: Nanotechnology for therapy and imaging of liver diseases. J Hepatol 2011;55:1461-1466.
21.
Doxorubicin Transdrug: Significant Increased Survival Rate in Patients with Advanced Hepatocellular Carcinoma Treated in a Phase II Clinical Trial. Bioalliance web document, 2009.
22.
Krishna AD, Mandraju RK, Kishore G, Kondapi AK: An efficient targeted drug delivery through apotransferrin loaded nanoparticles. PLoS One 2009;4:e7240.
23.
Wu DQ, Lu B, Chang C, et al: Galactosylated fluorescent labeled micelles as a liver targeting drug carrier. Biomaterials 2009;30:1363-1371.
24.
Liang HF, Chen CT, Chen SC, et al: Paclitaxel-loaded poly(γ-glutamic acid)-poly(lactide) nanoparticles as a targeted drug delivery system for the treatment of liver cancer. Biomaterials 2006;27:2051-2059.
25.
Medina SH, Tekumalla V, Chevliakov MV, Shewach DS, Ensminger WD, El-Sayed ME: N-acetylgalactosamine-functionalized dendrimers as hepatic cancer cell-targeted carriers. Biomaterials 2011;32:4118-4129.
26.
Seymour LW, Ferry DR, Anderson D, et al; Cancer Research Campaign Phase I/II Clinical Trials Committee: Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J Clin Oncol 2002;20:1668-1676.
27.
Jain NK, Jain SK: Development and in vitro characterization of galactosylated low molecular weight chitosan nanoparticles bearing doxorubicin. AAPS PharmSciTech 2010;11:686-697.
28.
Chauhan A, Zubair S, Nadeem A, Ansari SA, Ansari MY, Mohammad O: Escheriosome-mediated cytosolic delivery of PLK1-specific siRNA: potential in treatment of liver cancer in BALB/c mice. Nanomedicine (Lond) 2014;9:407-420.
29.
Yano J, Hirabayashi K, Nakagawa S, et al: Antitumor activity of small interfering RNA/cationic liposome complex in mouse models of cancer. Clin Cancer Res 2004;10:7721-7726.
30.
Tabernero J, Shapiro GI, LoRusso PM, et al: First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov 2013;3:406-417.
31.
Maeda H, Sawa T, Konno T: Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drugs SMANCS. J Control Release 2001;74:47-61.
32.
Farazuddin M, Dua B, Zia Q, Khan AA, Joshi B, Owais M: Chemotherapeutic potential of curcumin-bearing microcells against hepatocellular carcinoma in model animals. Int J Nanomedicine 2014;9:1139-1152.
33.
Khan AA, Alam M, Tufail S, Mustafa J, Owais M: Synthesis and characterization of novel PUFA esters exhibiting potential anticancer activities: an in vitro study. Eur J Med Chem 2011;46:4878-4886.
34.
Khan AA, Jabeen M, Khan AA, Owais M: Anticancer efficacy of a novel propofol-linoleic acid-loaded escheriosomal formulation against murine hepatocellular carcinoma. Nanomedicine (Lond) 2013;8:1281-1294.
35.
Zhou Q, Sun X, Zeng L, Liu J, Zhang Z: A randomized multicenter phase II clinical trial of mitoxantrone-loaded nanoparticles in the treatment of 108 patients with unresected hepatocellular carcinoma. Nanomedicine 2009;5:419-423.
36.
Moroz P, Jones SK, Gray BN: Status of hyperthermia in the treatment of advanced liver cancer. J Surg Oncol 2001;77:259-269.
37.
Sengupta P, Basu S, Soni S, et al: Cholesterol-tethered platinum II-based supramolecular nanoparticle increases antitumor efficacy and reduces nephrotoxicity. Proc Natl Acad Sci U S A 2012;109:11294-11299.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.